Bryan Johnson Longevity Protocol: A Clinical Interpretation of the Blueprint Stack

Who Is Bryan Johnson and What Is Blueprint?

Bryan Johnson is a 47-year-old technology entrepreneur who sold Braintree/Venmo to PayPal for $800 million in 2013. Starting around 2021, he began publicly funding what he calls "Project Blueprint," a personal experiment in which a team of roughly 30 physicians monitors his physiology around the clock and adjusts a rigid protocol of diet, exercise, sleep, and pharmacology.

Johnson has published much of his stack on blueprint.bryanjohnson.co and through peer-reviewed co-authored work. A 2023 paper in the journal Aging documented his epigenetic age measurements using multiple clocks (GrimAge, PhenoAge, DunedinPACE) and reported a composite biological age approximately 5.1 years below his chronological age. [1] That paper was co-authored with Morgan Levine and colleagues; it is the closest thing to peer review the protocol has received.

Why This Protocol Attracts Clinical Attention

The Blueprint protocol is notable not because it is proven to extend human lifespan, but because it is unusually transparent. Johnson publishes his bloodwork, organ imaging results, and medication changes publicly. That transparency allows clinicians to evaluate specific choices against existing trial evidence, which is precisely what this article does.

What the Protocol Is Not

Blueprint is not a validated medical treatment. No randomized controlled trial has tested this combination of interventions together. Each component below is evaluated on its own evidence base.

Rapamycin: The mTOR Inhibitor at the Center of Blueprint

Johnson has publicly stated he takes rapamycin intermittently (reportedly 13 mg once weekly, though dose has varied in public statements). Rapamycin inhibits mTORC1, the mechanistic target of rapamycin complex 1, a master regulator of cellular growth and autophagy. [2]

What Animal Data Shows

In the National Institute on Aging Interventions Testing Program, rapamycin extended median lifespan in genetically heterogeneous mice by 9-14% even when started at an age equivalent to 60 human years. [3] That finding, published in Nature in 2009, generated significant excitement because it suggested efficacy even with late-life initiation.

What Human Data Shows

No completed randomized trial has demonstrated that rapamycin extends human lifespan. The PEARL trial (NCT04488601) is evaluating low-dose rapamycin (6 mg weekly) in healthy adults aged 50-85, with results expected mid-decade. [4] The most relevant human data comes from a 2014 study in which everolimus (a rapamycin analogue) at 0.5 mg daily improved influenza vaccine responses in adults over 65 by approximately 20%, suggesting immunostimulatory effects at low doses. [5]

Safety Trade-offs

Rapamycin at immunosuppressive doses (used in transplant medicine) carries known risks: hyperlipidemia, impaired wound healing, mouth sores, and reduced vaccine efficacy. [6] At sub-immunosuppressive weekly doses, the risk profile is less characterized. The FDA has not approved rapamycin for any longevity indication. Johnson's use is off-label.

Metformin: The Diabetes Drug Repurposed for Aging

Johnson has reported taking metformin 1,500 mg/day. Metformin activates AMPK, lowers hepatic glucose output, and has been associated with reduced all-cause mortality in observational studies of diabetic populations. [7]

The TAME Trial

The Targeting Aging with Metformin (TAME) trial (NCT03451006) is the landmark NIH-funded study testing whether metformin 1,500 mg/day delays the composite onset of age-related diseases in non-diabetic adults aged 65-79. [8] Enrollment completed in 2023; primary results are not yet published. Until TAME reports, prescribing metformin to non-diabetic adults for longevity remains an extrapolation.

What Observational Data Suggests

A 2014 retrospective analysis in Diabetologia (N=78,241) found that diabetic patients on metformin had lower all-cause mortality than age-matched non-diabetic controls not on metformin. [9] This is an observational finding and subject to confounding, but it is the data point most frequently cited by longevity clinicians.

Vitamin B12 Depletion

Metformin reduces vitamin B12 absorption in approximately 30% of long-term users. [10] Johnson reportedly monitors B12 quarterly, consistent with the American Diabetes Association's recommendation to check B12 periodically in patients on long-term metformin. [11]

Acarbose: The Alpha-Glucosidase Inhibitor

Acarbose delays intestinal carbohydrate absorption by inhibiting alpha-glucosidase enzymes in the small intestine, blunting postprandial glucose spikes. In the NIA Interventions Testing Program, acarbose extended median male mouse lifespan by 22% and female lifespan by 5%. [12]

Johnson has stated he takes acarbose with meals to flatten glucose curves, a strategy consistent with continuous glucose monitor data he publishes showing post-meal glucose consistently below 120 mg/dL.

The primary human evidence for acarbose is in type 2 diabetes management. The STOP-NIDDM trial (N=1,429) showed acarbose reduced conversion from impaired glucose tolerance to type 2 diabetes by 25% over 3.3 years (P<0.0001) and also reduced cardiovascular event risk. [13] No trial has studied acarbose as a longevity agent in non-diabetic humans. GI side effects (flatulence, diarrhea) are reported in up to 50% of users at therapeutic doses.

Low-Dose Lithium: Neuroprotection Hypothesis

Johnson has reported taking lithium orotate at low doses (approximately 1 mg elemental lithium daily, far below the 60-180 mg elemental lithium used in psychiatric care). The rationale draws on epidemiological data linking naturally occurring lithium in drinking water to lower rates of dementia and suicide. [14]

A 2017 meta-analysis in The British Journal of Psychiatry found that higher residential lithium levels in drinking water were associated with reduced dementia incidence across five studies. [15] These are ecological associations. No randomized trial has confirmed that supplemental low-dose lithium prevents neurodegeneration in healthy adults. The FDA has not approved lithium orotate for any indication; lithium carbonate and lithium citrate are the approved pharmaceutical forms.

The Supplement Stack: Evidence Tiers

Johnson's published supplement list has exceeded 100 daily doses. This section organizes the highest-profile components by evidence quality.

Tier 1: Supported by Human RCT Data

Vitamin D3 (reported dose: 2,000-4,000 IU/day). VITAL (N=25,871) showed vitamin D supplementation reduced cancer mortality by 17% over 5.3 years in adults not taking fish oil concurrently. [16] The Endocrine Society guidelines recommend 1,500-2,000 IU/day for adults at risk of deficiency. [17]

Omega-3 fatty acids (EPA/DHA, reported 3-4 g/day). REDUCE-IT (N=8,179) demonstrated that icosapentaenoic acid (EPA) 4 g/day reduced major adverse cardiovascular events by 25% relative to placebo in high-risk patients already on statins. [18] Johnson's dose is in this range, though his cardiovascular risk baseline is low.

Zinc (reported 15 mg/day). The AREDS2 trial (N=4,203) confirmed that zinc 80 mg/day combined with antioxidants reduced progression of age-related macular degeneration by 25%. [19] Johnson's lower dose targets general immune function.

Tier 2: Promising Mechanistic Data, No Definitive Human RCT

NMN (nicotinamide mononucleotide, reported 500-1,000 mg/day). NMN is a precursor to NAD+, which declines approximately 50% between ages 40 and 60. [20] A 2023 randomized trial in Nature Aging (N=243) found NMN 300 mg/day improved gait speed in older adults over 12 weeks compared to placebo (P<0.05). [21] No trial has yet demonstrated lifespan extension in humans.

Lycopene (reported 20 mg/day). A 2020 meta-analysis in Nutrients (N=260,000 across 42 studies) found higher lycopene intake associated with a 26% lower risk of prostate cancer. [22] Association, not causation.

Fisetin (reported dose variable). Fisetin is a flavonoid with senolytic properties in mouse models; one 2019 study in EBioMedicine found it reduced senescent cell burden in aged mice by ~50%. [23] Human senolytics trials are underway (Mayo Clinic, NCT02848131) but none have reported longevity outcomes.

Tier 3: Theoretical or Very Early Data

Spermidine, astaxanthin, and several proprietary blends Johnson uses fall into this category. Mechanistic plausibility exists for autophagy induction (spermidine) [24] and oxidative stress reduction (astaxanthin), [25] but human RCT data is sparse or absent.

Diet: The Blueprint Eating Protocol

Johnson eats a fully plant-based diet of approximately 1,977 kcal/day, structured around a single early meal or a compressed eating window ending before 11 a.m. He calls the flagship meal "Green Giant" (broccoli, cauliflower, black lentils, mushrooms, hemp seeds with olive oil).

Caloric Restriction Evidence

The CALERIE-2 trial (N=218) tested 25% caloric restriction in non-obese adults over 2 years. Participants achieved only 12% restriction on average but showed significant reductions in cardiometabolic risk factors including LDL cholesterol, blood pressure, and inflammatory markers. [26] Johnson's reported intake represents moderate restriction for his body weight.

Time-Restricted Eating

A 2022 randomized trial in the New England Journal of Medicine (N=139) compared time-restricted eating (8-hour window) to unrestricted eating in patients with metabolic syndrome over 12 weeks. The time-restricted group lost 2.4 kg more and showed greater reductions in systolic blood pressure. [27] Johnson's compressed early window aligns with this approach, though his window is tighter than most studied protocols.

Olive Oil

Johnson reportedly consumes 30+ mL of extra-virgin olive oil daily. The PREDIMED trial (N=7,447) found a Mediterranean diet supplemented with extra-virgin olive oil reduced major cardiovascular events by 31% relative to a low-fat control diet. [28] The polyphenol content of EVOO, particularly oleocanthal, has demonstrated anti-inflammatory activity in vitro comparable to ibuprofen at low doses. [29]

Exercise Protocol

Johnson performs approximately one hour of structured exercise per day, with a mix of high-intensity intervals, resistance training, and flexibility work. He has reported VO2 max scores in the 95th percentile for his age group.

A 2022 analysis in the Journal of the American College of Cardiology (N=122,007) found that adults in the top quartile of cardiorespiratory fitness had a 45% lower all-cause mortality rate than those in the lowest quartile, independent of other risk factors. [30] VO2 max may be the single strongest individual predictor of longevity currently measurable, which makes Johnson's reported fitness level clinically meaningful regardless of his supplement protocol.

Biomarker Targets: How Johnson Sets Goals

Johnson publishes specific biomarker targets that are generally more aggressive than standard clinical thresholds. His reported targets include ApoB <60 mg/dL, fasting glucose <85 mg/dL, HbA1c <5.0%, and hsCRP <0.3 mg/L.

ApoB

Standard clinical labs flag ApoB above 130 mg/dL as high. Johnson's target of <60 mg/dL aligns with the 2021 ESC/EAS cardiovascular prevention guidelines, which state that for very-high-risk patients, an LDL-C <55 mg/dL (roughly corresponding to ApoB <65 mg/dL) is the treatment target. [31] Applying very-high-risk thresholds to a healthy 47-year-old is aggressive by current U.S. Guideline standards but is supported by Mendelian randomization data showing lifelong low ApoB dramatically reduces atherosclerotic events. [32]

hsCRP

His hsCRP target of <0.3 mg/L is below the American Heart Association's low-risk cutoff of <1.0 mg/L. [33] The JUPITER trial (N=17,802) demonstrated that statin therapy in patients with LDL <130 mg/dL but hsCRP >2.0 mg/L reduced major cardiovascular events by 44%. [34] Johnson's dietary and exercise protocol appears sufficient to achieve his hsCRP target without statin therapy, based on his published labs.

Epigenetic Age Testing: What the Clocks Actually Measure

Johnson has repeatedly publicized results from biological age tests, primarily DunedinPACE, GrimAge, and PhenoAge. These clocks use methylation patterns at specific CpG sites in DNA to estimate biological aging rate.

A 2022 paper in Nature Aging validated DunedinPACE in 1,037 participants from the Dunedin cohort, confirming it predicts longitudinal decline in physical and cognitive function better than single-timepoint clocks. [35] Critically, the same paper noted that DunedinPACE measures the pace of aging at one moment and can fluctuate with short-term lifestyle changes, acute illness, and even sleep deprivation. A single favorable score does not confirm slower overall aging trajectory.

Johnson's reported DunedinPACE score of 0.69 (where 1.0 = population average aging rate) means he is aging at roughly 69% of the average rate according to that clock at the time of testing. This is a genuinely unusual result; the 5th percentile in the Dunedin cohort was approximately 0.80. [35] The clinical interpretation is that his methylation pattern is consistent with slower biological aging, not that he has proven any single intervention caused it.

Finasteride and Testosterone: The Hormonal Layer

Johnson has publicly discussed using finasteride 1 mg/day for androgenic alopecia prevention, which is standard FDA-approved therapy. [36] He has also referenced testosterone monitoring and, in some public disclosures, testosterone optimization, though details are less consistently published than his other interventions.

Finasteride inhibits 5-alpha-reductase, blocking conversion of testosterone to dihydrotestosterone (DHT). The PCPT trial (N=18,882) found finasteride 5 mg/day reduced prostate cancer incidence by 24.8% over 7 years but was associated with a small increase in high-grade tumors (a finding whose clinical significance remains debated). [37] At 1 mg/day, the dose Johnson uses, the primary indication is hair loss rather than prostate cancer prevention.

What Clinicians Should Know Before Patients Ask

Patients increasingly bring longevity protocols derived from Blueprint into clinical consultations. Several practical points apply.

Off-Label Rx Prescribing

Rapamycin, metformin (in non-diabetics), and acarbose (in non-diabetics) are all off-label for longevity. Prescribing them requires informed consent documentation, baseline labs (CMP, CBC, lipids, HbA1c), and monitoring protocols. No major U.S. Guideline body (ACC, AHA, ADA, Endocrine Society) currently endorses any of these agents for longevity in metabolically healthy adults outside a clinical trial.

Drug Interactions

Rapamycin is metabolized by CYP3A4. Co-administration with strong CYP3A4 inhibitors (ketoconazole, clarithromycin, grapefruit juice) can increase rapamycin blood levels several-fold. [6] Metformin interacts with contrast dye and should be held 48 hours before iodinated contrast procedures. [38]

Monitoring Frequency

Johnson's protocol involves frequent laboratory monitoring (reportedly every 3 months for a full panel). For patients attempting even a partial version, the ADA recommends annual B12 checks on metformin and renal function monitoring at least every 6 months in patients on metformin above 1,000 mg/day. [11]

Safety Signals and Known Unknowns

The combination of rapamycin plus metformin has not been tested in a human RCT. An ITP mouse study found the combination produced additive but not synergistic lifespan extension compared to either drug alone, [39] but mouse pharmacokinetics differ substantially from human pharmacokinetics.

The central unknown in Blueprint is whether the epigenetic clock improvements Johnson reports reflect genuine biological age change or are a direct pharmacological effect on methylation patterns that does not translate to extended healthspan. Rapamycin itself has been shown to alter DNA methylation in ways that score favorably on epigenetic clocks without necessarily extending cellular function. [40] This confound is not unique to Johnson; it applies to any protocol evaluated primarily via clock scores.

FAQ